Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29459625 | 0.90 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| SCHEMBL5108263 | 0.90 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| Hydrochloric Acid SCHEMBL8168636 | 0.90 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| SCHEMBL27483471 | 0.89 | MRGPRX2 (0.76) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| SCHEMBL154048 | 0.86 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| SCHEMBL29449917 | 0.86 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| SCHEMBL29583693 | 0.86 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1 | |
| Methoxymethane SCHEMBL27466715 | 0.85 | MRGPRX2 (0.94) | MRGPRX2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL27754570 | 0.85 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRD1OPRK1 | |
| SCHEMBL27147236 | 0.82 | MRGPRX2 (0.67) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995056-B2 | Direct C—H amination and aza-annulation | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-05-04 | — | — | US | disclosed |
| US-20190152892-A1 | DIRECT C-H AMINATION AND AZA-ANNULATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995056-B2 | Direct C—H amination and aza-annulation | AOC3, ALKBH3, AZI2 | MRGPRX2 3835/4885OPRM1 3661/4885OPRD1 3398/4885 |
| US-20190152892-A1 | DIRECT C-H AMINATION AND AZA-ANNULATION | AOC3, ALKBH3, AZI2 | MRGPRX2 3861/4885OPRM1 3566/4885OPRD1 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.